èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Verona Pharma plc ã¯ãå»çããŒãºãæºããããŠããªãåŒåžåšçŸæ£ã®æ²»çè¬ã®éçºãšåååã«æ³šåããŠããŸããå瀟ã®è£œååè£ã¯ãåžå
¥åŒã®ãã¹ããžãšã¹ãã©ãŒãŒ (PDE) 3 ããã³ PDE4 é
µçŽ ã®äºéé»å®³å€ã§ãããšã³ã·ãã§ã³ããªã³ã§ããåäžååç©ã§æ°ç®¡æ¯æ¡åŒµè¬ãšæççè¬ã®äž¡æ¹ã®åããããæ
¢æ§é塿§èºçŸæ£ã忝ãå¢èæ§ç·ç¶çã®æ²»çè¬ãšããŠç¬¬ 2 çžèšåºè©Šéšãè¡ãããŠããŸããå瀟ã¯ãããã©ã€ã¶ãŒããã©ã€ããŠããŒåžå
¥åšãå å§åŒå®éåŽé§åŒåžå
¥åšã® 3 ã€ã®è£œå€ã§ãšã³ã·ãã§ã³ããªã³ãéçºããŠããŸãããŸããCOVID-19 ã®æ²»çè¬ãšããŠãšã³ã·ãã§ã³ããªã³ã®éçºã«ã泚åããŠããŸããVerona Pharma plc 㯠2005 幎ã«èšç«ãããè±åœãã³ãã³ã«æ¬ç€Ÿã眮ããŠããŸãã